NCT04028739

Brief Summary

A randomized, open-label, cross-over, single administration study to compare bioavailability of curcumin in health adults

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 23, 2019

Completed
8 days until next milestone

Study Start

First participant enrolled

July 31, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 29, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 29, 2019

Completed
Last Updated

December 6, 2019

Status Verified

December 1, 2019

Enrollment Period

4 months

First QC Date

July 17, 2019

Last Update Submit

December 4, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Cmax

    Maximum concentration at steady state

    12hours

  • AUC

    Area under the concentration-time curve at steady state

    12hours

Study Arms (3)

Theracurmin CR-033P

EXPERIMENTAL

1 Capsule with 150mL water, Single, curcumin 90mg/day

Dietary Supplement: curmin

Theracurmin CR-031P

EXPERIMENTAL

3 Capsule with 150mL water, Single, curcumin 90mg/day

Dietary Supplement: curmin

Curcumin

EXPERIMENTAL

1 Capsule with 150mL water, Single, curcumin 90mg/day

Dietary Supplement: curmin

Interventions

curminDIETARY_SUPPLEMENT

curcumin 90mg/day cross-over

Also known as: Theracurmin CR-033P, Theracurmin CR-031P, Curcumin
CurcuminTheracurmin CR-031PTheracurmin CR-033P

Eligibility Criteria

Age19 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy adult 19 to 60 years
  • BMI 18.0\~30.0kg/m2 at screening
  • Subject who was given, and fully understood, the information about the study, and has provided voluntary written informed consent to participate in the study and agreed to comply with the study requirements.

You may not qualify if:

  • A person with clinically significant disease corresponding to cardiovascular, respiratory, liver, kidney, digestive system, blood/tumor system, endocrine system, immune system, neuropsychiatry or who has a history within the last 6 months.
  • A person with a history of gastrointestinal disease or surgery (except for simple cecal surgery or hernia surgery) that may affect the absorption of food for clinical research.
  • Persons who have an irritable reaction to foods containing turmeric or other drugs and food.
  • Those who took medicines within 7 days before the first intake of food for clinical research.
  • Food for Clinical Research If you have consumed foods containing turmeric (eg, radishes, curry) within 7 days before the first intake of food, or you can't consume until the day of intake of food for the last clinical study.
  • Those who have participated in other clinical studies within 90 days prior to the first intake of food for clinical research.
  • Women who are pregnant or lactating during screening, or who plan to become pregnant during clinical research. A person who is deemed unsuitable for participating in this clinical study because of other reasons.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Korea Kuro Hospital

Seoul, South Korea

Location

MeSH Terms

Interventions

Curcumin

Intervention Hierarchy (Ancestors)

DiarylheptanoidsHeptanesAlkanesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Study Officials

  • Hyewon Chung

    Korea University Guro Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2019

First Posted

July 23, 2019

Study Start

July 31, 2019

Primary Completion

November 29, 2019

Study Completion

November 29, 2019

Last Updated

December 6, 2019

Record last verified: 2019-12

Locations